Immix Biopharma, Inc. (IMMX) research
Immix Biopharma, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $11.92
- As of
Immix Biopharma, Inc. (IMMX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-07.
As of . Source: SEC EDGAR filings for IMMX. Method and limitations.
Share the IMMX intelligence card
See IMMX live in the terminal
Track IMMX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live IMMX terminal, freeActive signals for IMMX
- highCONSENSUS_BUY
4 tracked funds increased IMMX this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 58% of IMMX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +572% to IMMX (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in IMMX
- mediumNEW_POSITION
TWO SIGMA INVESTMENTS, LP new position in IMMX
FREE, NO ACCOUNT
Every signal on IMMX, as it fires
You are seeing 5 of 19 signals recorded on IMMX since 2026-05-17.
The five above landed across 2 days. The other 14 were recorded on 2 other days. 14 of the 19 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IMMX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 45258H106 · 2026Q2 | $21.3M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 45258H106 · 2026Q2 | $5.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 45258H106 · 2026Q2 | $960K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45258H106 · 2026Q2 | $414K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IMMX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IMMX against its peers
IMMX's return on equity of -31.4% ranks in the 70th percentile of 21 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | IMMX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 49.8M | n/a | 13 |
| Operating margin | n/a | -142.7% | n/a | 12 |
| Net margin | n/a | -132.8% | n/a | 12 |
| Return on equity | -31.4% | -37.3% | 70 | 21 |
Peers (22): CLYM, AVTX, TBPH, ARDX, RIGL, OLMA, WVE, CADL, GERN, FDMT, SLDB, SGP, LXRX, DSGN, ACHV, ABUS, JANX, SANA, GYRE, PHAR, ANNX, DBVT. Left out: IVA (period gap), ETRA (no annual filing), HELP (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (IMMX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IMMX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IMMXand get the insider, 13F, options, and confluence read in one view.